# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

F. Proprietary and Established Names: C.f.a.s. DAT Qualitative Plus Clinical calibrator Control Set DAT Clinical

# G. Regulatory Information:

1. Regulation section: 21 CFR $\ S$ 862.3280, Clinical toxicology calibrator 21 CFR $\$ 862.3200$ , Clinical toxicology control material

2. Classification: Class II Class I - reserved

3. Product code: DKB; DIF

4. Panel: Toxicology (91)

# H. Intended Use:

1. Intended use: See indications for use below.

# 2. Indications for use:

The C.f.a.s. DAT Qualitative Plus Clinical calibrator is designed for the   
qualitative calibration of the Roche assays for drugs of abuse in human urine on automated clinical chemistry analyzers.   
The Control Set DAT Clinical is for use as an assayed control in the Roche test system for qualitative and semiquantitative determination of drugs of abuse in human urine on automated clinical chemistry analyzers.

3. Special conditions for use statement(s): For Prescription Use Only

4. Special instrument requirements: For use on Roche/Hitachi analyzers and cobas c analyzers

# I. Device Description:

C.f.a.s. DAT Qualitative Plus Clinical calibrators contain a mixture of 10 different drugs, prepared by quantitative addition of drug or drug metabolite to drug-free human urine. Drugs included are amphetamines, barbituates, benzodiazepines, cannabinoids, cocaine, methadone, methaqualone, opiates, phencyclidine, and propoxyphene. The calibrator set contains a single level for each drug in a drug mixture. Drug concentrations are verified by gas chromatography/mass spectrometry (GC/MS). Drugs or drug metabolites and their respective levels included are as follows:

Amphetamines: $5 0 0 ~ \mathrm { { n g / m L } }$ Barbituates: $2 0 0 ~ \mathrm { { n g / m L } }$ Benzodiazepines: $1 0 0 ~ \mathrm { { n g / m L } }$ Cannabinoids: $5 0 ~ \mathrm { n g / m L }$ Cocaine: $3 0 0 ~ \mathrm { { n g / m L } }$ Methadone: $3 0 0 ~ \mathrm { { n g / m L } }$ Methaqualone: $3 0 0 ~ \mathrm { { n g / m L } }$ Opiates: $3 0 0 ~ \mathrm { { n g / m L } }$ Phencyclidine: $2 5 ~ \mathrm { n g / m L }$ Propoxyphene: $3 0 0 ~ \mathrm { { n g / m L } }$

Control Set DAT Clinical controls contain a mixture of 10 different drugs, prepared by quantitative addition of drug or drug metabolite to drug-free human urine. Drugs included are amphetamines, barbituates, benzodiazepines, cannabinoids, cocaine, methadone, methaqualone, opiates, phencyclidine, and propoxyphene. Drug concentrations are verified by gas chromatography/mass spectrometry (GC/MS). Target concentrations are established at $\pm 2 5 \%$ of the assay cutoff.

Donors for the pools of human urine used in the preparation of this product all screened negative in annual serum testing for hepatitis B surface antigen (HBsAg), and for antibodies to HIV type 1, HIV type 2, and hepatitis C (anti-HCV), using FDA accepted test methods.

# J. Substantial Equivalence Information:

1. Predicate device name: Preciset DAT Plus I Calibrators Preciset DAT Plus II and Cfas DAT Qualitative Plus Calibrators Control Set DAT I, Control Set DAT II, Control Set DAT III

2. Predicate 510(k) number(s): k031775; k033306; k080183

3. Comparison with predicate:

<table><tr><td colspan="2" rowspan="1">New Device (Calibrator)</td><td colspan="3" rowspan="1">Predicate Device</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">C.f.a.s. DATQualitative PlusClinicalcalibrator</td><td colspan="1" rowspan="1">Preciset DATPlus I Calibrators</td><td colspan="1" rowspan="1">Preciset DATPlus II</td><td colspan="1" rowspan="1">C.f.a.s DATQualitative PlusCalibrators</td></tr><tr><td colspan="1" rowspan="1">IntendedUse</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Intended for thecalibration of theRoche assays fordrugs of abuse inhuman urine onautomatedclinical chemistryanalyzers.</td><td colspan="1" rowspan="1">Intended for thecalibration of theRoche assays fordrugs of abuse inhuman urine onautomatedclinical chemistryanalyzers.</td><td colspan="1" rowspan="1">Designed for thecalibration of theRoche assays fordrugs of abuse inhuman urine onautomatedclinical chemistryanalyzers.</td></tr><tr><td colspan="1" rowspan="1">Analytes</td><td colspan="1" rowspan="1">AmphetaminesBarbituatesBenzodiazepinesCannabinoidsCocaineMethadoneMethaqualoneOpiatesPhencyclidinePropoxyphene</td><td colspan="1" rowspan="1">AmphetaminesBarbituatesBenzodiazepinesCannabinoidsCocaineMethadoneOpiatesPhencyclidinePropoxyphene</td><td colspan="1" rowspan="1">BenzodiazepinesOpiates</td><td colspan="1" rowspan="1">BarbituatesBenzodiazepinesCocaineMethadoneOpiatesPhencyclidinePropoxyphene</td></tr><tr><td colspan="1" rowspan="1">Form</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Liquid</td><td colspan="1" rowspan="1">Liquid</td><td colspan="1" rowspan="1">Liquid</td></tr><tr><td colspan="1" rowspan="1">Traceability</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">GC/MS</td><td colspan="1" rowspan="1">GC/MS</td><td colspan="1" rowspan="1">GC/MS</td></tr><tr><td colspan="1" rowspan="1">Matrix</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Human urinebased</td><td colspan="1" rowspan="1">Human urinebased</td><td colspan="1" rowspan="1">Human urinebased</td></tr><tr><td colspan="1" rowspan="1">Number ofLevels</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">Up to 6</td><td colspan="1" rowspan="1">Up to 6</td><td colspan="1" rowspan="1">1</td></tr></table>

<table><tr><td rowspan=1 colspan=2>New Device (Control)</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Control SetDATClinical</td><td rowspan=1 colspan=1>Control Set DAT I, Control Set DAT II, Control Set DAT III</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>For use as an assayed control in the Roche test system for thequalitative and semiquantitative determination of drugs ofabuse in human urine on automated clinical chemistryanalyzers.</td></tr><tr><td rowspan=1 colspan=1>Analytes</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Amphetamines (d-methamphetamine)Barbituates (secobarbital)Benzodiazepines (nordiazepam)Cannabinoids (Î” THC-COOH)Cocaine (benzoylecgonine)Methadone (dl-methadone)Methaqualone (methaqualone)Opiates (d-morphine)PCP (phencyclidine)Propoxyphene (propoxyphene)</td></tr><tr><td rowspan=1 colspan=1>Form</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Liquid</td></tr><tr><td rowspan=1 colspan=1>Traceability</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>GC/MS</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Human urine based</td></tr><tr><td rowspan=1 colspan=1>Number ofLevels</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

Guidance for Industry and FDA Staff: Bundling Multiple Devices or Multiple Indications in a Single Submission

Guidance for Industry and FDA Staff - Assayed and Unassayed Quality Control Material

Guidance for Industry and FDA Staff - Use of Symbols on Labels and in Labeling of In Vitro Diagnostic Devices Intended for Professional Use

Guidance for Industry - Abbreviated 510(k) Submissions for In Vitro Diagnostic

Calibrators; Final

L. Test Principle: Not applicable

# M. Performance Characteristics (if/when applicable):

1. Analytical performance: a. Precision/Reproducibility: Not applicable b. Linearity/assay reportable range: Not applicable c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Drug concentrations in C.f.a.s. DAT Qualitative Plus Clinical calibrator were verified by gas chromatography/mass spectrometry (GC/MS). C.f.a.s. DAT Qualitative Plus Clinical calibrator is traceable to a primary reference method (GC/MS).

Drug concentrations in Control Set DAT Clinical were verified by gas chromatography/mass spectrometry (GC/MS). Target concentrations are established at $\ b { \cdot \pm 2 5 \% }$ of the assay cutoff.

Control Set DAT Clinical controls is traceable to a primary reference method (GC/MS).

The protocols for establishing shelf-life and open-vial stability were reviewed and adequate.

d. Detection limit: Not Applicable e. Analytical specificity: Not Applicable

f. Assay cut-off: Not Applicable

2. Comparison studies:

a. Method comparison with predicate device:

Not Applicable b. Matrix comparison: Not Applicable

3. Clinical studies:

a. Clinical Sensitivity: Not Applicable

b. Clinical specificity: Not Applicable

c. Other clinical supportive data (when a. and b. are not applicable): Not Applicable

4. Clinical cut-off: Not Applicable

5. Expected values/Reference range: Not Applicable

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.